# US 2010/0168380 A1 · Process for synthesizing cyclic peptide compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168380 A1
- Document ID: US20100168380A1
- Status: Published application
- Kind: A1
- Application number: 12/593,221
- Filed: 2008-03-26
- Published: 2010-07-01
- Earliest claimed: 2007-03-26
- Assignees: The University of Tokyo
- Inventors: Hiroaki Suga; Hiroshi Murakami; Yuki Goto; Yusuke Yamagishi; Hiroshi Ashigai; Yusuke Sako
- Web page: https://patentgrep.com/patent/US20100168380A1

## CPC

- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C12N 15/67: General methods for enhancing the expression
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The objective is to provide a novel process for synthesizing a cyclic peptide compound. It is also an objective to provide a novel cyclic peptide compound. The novel process for synthesizing a cyclic peptide compound comprises the steps of: (1) translationally synthesizing a non-cyclic peptide compound having in a molecule a functional group 1 and a functional group 2, which are a pair of functional groups capable of reacting to form a bond, and (2) cyclizing the non-cyclic peptide compound by the reaction of the functional groups 1 and 2 to form a bond. The novel cyclic peptide compound can be synthesized by the process.

## Claims

### Claim 1

A process for synthesizing a cyclic peptide compound, comprising the steps of:
(1) translationally synthesizing a non-cyclic peptide compound containing a functional group 1 and a functional group 2, which are a pair of functional groups capable of reacting to form a bond; and
(2) cyclizing the non-cyclic peptide compound by the reaction of the functional group 1 and the functional group 2 to form a bond.

### Claim 2 (depends on 1)

The process of claim 1, wherein the step (1) comprises the substeps of:
(a) providing a ribozyme capable of catalyzing an aminoacylation reaction of a tRNA with any amino acid compound;
(b) providing an initiator tRNA and an amino acid compound having the functional group 1 for use as a substrate for the acylation reaction by the ribozyme;
(c) performing an aminoacylation of the initiator tRNA with the amino acid compound having the functional group 1 using the ribozyme;
(d) providing a cell-free translation system which contains at least an amino acid compound having the functional group 2 and a tRNA to be aminoacylated with the amino acid compound having the functional group 2, and is free of methionine;
(e) providing a template DNA for forming an mRNA having at desired positions a codon corresponding to an anticodon of the initiator tRNA, and a codon corresponding to an anticodon of the tRNA to be aminoacylated with the amino acid compound having the functional group 2; and
(f) adding the aminoacylated initiator tRNA obtained in the substep (c) and the template DNA to the cell-free translation system to synthesize the non-cyclic peptide compound.

### Claim 3 (depends on 1)

The process of claim 1, wherein the step (1) comprises the substeps of:
(a) providing a ribozyme capable of catalyzing an aminoacylation reaction of a tRNA with any amino acid compound;
(b) providing an initiator tRNA and an amino acid compound having the functional group 1 for use as a substrate for the acylation reaction by the ribozyme;
(c) performing an aminoacylation of the initiator tRNA with the amino acid compound having the functional group 1 using the ribozyme;
(d) providing a tRNA having an orthogonal relationship to a natural aminoacyl-tRNA synthetase present in a cell-free translation system, and an amino acid compound having the functional group 2, for use as a substrate for the acylation reaction by the ribozyme;
(e) performing an aminoacylation of the tRNA with the amino acid compound having the functional group 2 using the ribozyme;
(f) providing a cell-free translation system free of methionine;
(g) providing a template DNA for forming an mRNA having at desired positions a codon corresponding to an anticodon of the initiator tRNA, and a codon corresponding to an anticodon of the tRNA; and
(h) adding the aminoacylated initiator tRNA obtained in the substep (c), the tRNA aminoacylated in the substep (e) with the amino acid compound having the functional group 2, and the template DNA to the cell-free translation system to synthesize the non-cyclic peptide compound.

### Claim 4 (depends on 1)

The process of claim 1, wherein the step (1) comprises the substeps of:
(a) providing a ribozyme capable of catalyzing an aminoacylation reaction of a tRNA with any amino acid compound;
(b) providing a tRNA having an orthogonal relationship to a natural aminoacyl-tRNA synthetase present in a cell-free translation system, and an amino acid compound having the functional group 1, for use as a substrate for the acylation reaction by the ribozyme;
(c) performing an aminoacylation of the tRNA with the amino acid compound having the functional group 1 using the ribozyme;
(d) providing a cell-free translation system containing at least an amino acid compound having the functional group 2, a tRNA to be aminoacylated with the amino acid compound having the functional group 2, an initiator tRNA, methionine, and a methionyl-tRNA synthetase;
(e) providing a template DNA for forming an mRNA having at desired positions a codon corresponding to an anticodon of the tRNA to be aminoacylated with the amino acid compound having the functional group 1, and a codon corresponding to an anticodon of the tRNA to be aminoacylated with the amino acid compound having the functional group 2; and
(f) adding the aminoacylated tRNA obtained in the substep (c) and the template DNA to the cell-free translation system to synthesize the non-cyclic peptide compound.

### Claim 5 (depends on 1)

The process of claim 1, wherein the step (1) comprises the substeps of:
(a) providing a ribozyme capable of catalyzing an aminoacylation reaction of a tRNA with any amino acid compound;
(b) providing a tRNA having an orthogonal relationship to a natural aminoacyl-tRNA synthetase present in a cell-free translation system, and an amino acid compound having the functional group 1, for use as a substrate for the acylation reaction by the ribozyme;
(c) performing an aminoacylation of the tRNA with the amino acid compound having the functional group 1 using the ribozyme;
(d) providing a tRNA having an orthogonal relationship to a natural aminoacyl-tRNA synthetase present in a cell-free translation system, and an amino acid compound having the functional group 2, for use as a substrate for the acylation reaction by the ribozyme;
(e) performing an aminoacylation of the tRNA with the amino acid compound having the functional group 2 using the ribozyme;
(f) providing a cell-free translation system containing at least an initiator tRNA, methionine, and a methionyl-tRNA synthetase;
(g) providing a template DNA for forming an mRNA having at desired positions a codon corresponding to an anticodon of the tRNA to be aminoacylated with the amino acid compound having the functional group 1, and a codon corresponding to an anticodon of the tRNA to be aminoacylated with the amino acid compound having the functional group 2; and
(h) adding the aminoacylated tRNA obtained in the substep (c), the aminoacylated tRNA obtained in the substep (e), and the template DNA to the cell-free translation system to synthesize the non-cyclic peptide compound.

### Claim 6 (depends on 2, 3, 4, 5)

The process of any one of claims 2-5, wherein the ribozyme capable of catalyzing the aminoacylation reaction of tRNA in any amino acid compound consists of the base sequence (I) or (II) below:
(I)
GGAUCGAAAGAUUUCCGCGGCCCCGAAAGGGGAUUAGCGUUAGGU
(II)
GGAUCGAAAGAUUUCCGCAUCCCCGAAAGGGUACAUGGCGUUAGGU.

### Claim 7 (depends on 1)

The process of claim 1, wherein the pair of functional groups 1 and 2 is one of the following pairs (A) to (C)
wherein X1 is Cl or Br, and Ar is an aromatic ring optionally having a substituent.

### Claim 8 (depends on 2)

The process of claim 2, wherein
the amino acid compound in the substep (b) is a compound of formula (1):
wherein R1 and R2 represent a hydrogen atom or any substituent connected by carbon; and
the amino acid compound in the substep (d) is cysteine.

### Claim 9 (depends on 3)

The process of claim 3, wherein the amino acid compound in the substep (b) is a compound of formula (2), and the amino acid compound in the substep (d) is a compound of formula (3)
wherein R1 and R2 are as defined above, and Z1 represents any substituent.

### Claim 10 (depends on 4)

The process of claim 4, wherein
the amino acid compound in the substep (b) is a compound of formula (4)
wherein m is an integer of 1 to 10; and
the amino acid compound in the substep (d) is cysteine.

### Claim 11 (depends on 5)

The process of claim 5, wherein the amino acid compound in the substep (b) is a compound of formula (5), and the amino acid compound in the substep (d) is a compound of formula (6)
wherein m is as defined above.

### Claim 12 (depends on 5)

The process of claim 5, wherein the amino acid compound in the substep (b) is a compound of formula (7), and the amino acid compound in the substep (d) is a compound of formula (8)
wherein Z1 is as defined above.

### Claim 13

A cyclic peptide compound represented by formula (9) or (10)
wherein AA represents a peptide chain comprising 2-10 amino acid residues, BB represents a peptide chain comprising one amino acid residue or a peptide chain comprising 2-5 amino acid residues, L1 represents a divalent linking group, and Ar is as defined above.

### Claim 14 (depends on 13)

The cyclic peptide compound of claim 13 represented by formula (11) or (12)

### Claim 15

A cyclic peptide compound represented by formula (13)
wherein m1 and m2 independently represent an integer of 1 to 10, and AA and BB are as defined above.

### Claim 16 (depends on 15)

The cyclic peptide compound of claim 15 represented by formula (14)
wherein m1 and m2 are as defined above.
